

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



(Incorporated in the Cayman Islands as an exempted company with limited liability)

(Stock code: 1873)

CHANGE IN EXECUTIVE DIRECTOR'S RESPONSIBILITIES AND APPOINTMENT OF CO-CHIEF FINANCIAL OFFICER

The board of directors (the “**Board**”) of Viva Biotech Holdings (the “**Company**”, together with its subsidiaries, the “**Group**”) announce that, (i) Mr. REN Delin (“**Mr. Ren**”), an executive director of the Company will begin serving as the general manager and chief executive officer of Viva Biotech (Shanghai) Ltd. (維亞生物科技(上海)有限公司, “**Viva Shanghai**”) and will cease to serve as the president of the Company; and (ii) Mr. XIONG Wei (“**Mr. Xiong**”) has been appointed as the Co-Chief Financial Officer of the Company.

CHANGE IN EXECUTIVE DIRECTOR'S RESPONSIBILITIES

It is announced that Mr. Ren, an executive director of the Company will begin serving as the chief executive officer of Viva Shanghai (an indirect non-wholly owned subsidiary of the Company) and will concurrently cease to serve as the president of the Company with effect from December 1, 2023. Mr. Ren will continue to serve on the board of the Company as an executive director and will remain as a member of Viva Shanghai’s senior management team. He will serve as the general manager and chief executive officer of Viva Shanghai and will remain responsible for the overall management of the Group’s contract research organization (CRO) and drug discovery functions. The other roles and responsibilities previously held by Mr. Ren as president of the Company will be assumed by Mr. MAO Chen Cheney (“**Mr. Mao**”), the chief executive officer of the Group and chairman of the Company. The change in executive responsibilities will enable Mr. Ren to focus more of his attention to leading the Group’s CRO and drug discovery businesses.

Biographical information of Mr. Ren and Mr. Mao are set out in the Company’s annual report for the year ended December 31, 2022 which was published on April 26, 2023. Save for the information set out above, there is no other information to be disclosed pursuant to the requirements of the provisions under Rule 13.51(2) of the Listing Rules nor is there any other matter that needs to be brought to the attention of the shareholders of the Company in relation to the change of the executive responsibilities of Mr. Ren.

APPOINTMENT OF CO-CHIEF FINANCIAL OFFICER

It is announced that Mr. Xiong will be appointed as a Co-Chief Financial Officer of the Group with effect from December 1, 2023, and in such role, he will be reporting to Mr. Mao. Mr. Xiong will be responsible for jointing leading the Group's financial management and capital market related affairs along with Mr. WANG Zheren (“**Mr. Wang**”), the Group's current Chief Financial Officer. Mr. Xiong will be primarily focused on the financial management of the Group's contract design and manufacturing (CDMO) and commercialization services while Mr. Wang will be primarily focused on the financial management of the Group's CRO and drug discovery services.

Mr. Xiong, aged 40, joined our Group in November 2020 as part of the Group's acquisition of Zhejiang Langhua Pharmaceutical Co., Ltd. (浙江朗華製藥有限公司, “**Langhua Pharmaceutical**”), he currently serves as the financial director of Langhua Pharmaceutical and is primarily responsible for its financial management. Mr. Xiong joined Langhua Pharmaceutical in September 2018. Prior to that, Mr. Xiong was employed by Donghaixiang Group Co., Ltd. (東海翔集團有限公司) from November 2011 to September 2018 where he last served as the executive vice general manager and financial director. He was employed by Zhejiang Yongtai Technology Co., Ltd. (浙江永太科技股份有限公司) from May 2007 to November 2011 where he last served as the investment director and securities business representatives and by CITIC Securities where he last served as an industry analyst from July 2005 to November 2006.

Mr. Xiong graduated from the Huazhong University of Science and Technology School of Economics (華中科技大學經濟學院) with a degree in international economics and trade and from the Zhongnan University of Economics and Law (中南財經政法大學) with a degree in law in June 2005. He is qualified to serve as a board secretary for companies listed on the Shanghai Stock Exchange and Shenzhen Stock Exchange, and has been qualified as a senior economist since November 2023.

The Board would like to take this opportunity to welcome Mr. Xiong to his new appointment with the Group.

By order of the Board
Viva Biotech Holdings
Mao Chen Cheney
Chairman and Chief Executive Officer

Hong Kong, December 1, 2023

As at the date of this announcement, the Board comprises three Executive Directors, namely, Mr. Mao Chen Cheney (Chairman), Mr. Wu Ying and Mr. Ren Delin; a Non-executive Director, namely, Mr. Wu Yuting; and three Independent Non-executive Directors, namely, Mr. Fu Lei, Ms. Li Xiangrong and Mr. Wang Haiguang.